Recipharm streamlines operations by selling oral solid dosage manufacturing site

Astrea Pharma will be the new owner of the facility at Fontaine-lès-Dijon

Recipharm has kicked off 2022 with a move to aid its operations streamlining strategy - an agreement to sell its Fontaine-lès-Dijon, site to Astrea Pharma.

At this oral solid dosage site, Recipharm has developed extensive experience manufacturing and packaging tablets and capsules.

For Astrea Pharma, a newly established CDMO focused on small molecule oral solid and aseptic dosages, acquiring this site suits its ambitions to grow a broad range of different processing, filling and packaging technologies, as well as a wide geographical reach.

According to Elie Vannier, Chairman of Astrea Pharma, the transaction is also the company's first investment.

As the site's new owner, Astrea will invest in people and eqipment to make it a state-of-the-art facility.

Recipharm's CEO Marc Funk said the divestment will help strengthen the company's financial position. He added: " ... we see it as a positive step in streamlining our operations and consolidating our position as a top five global CDMO."

ABOUT RECIPHARM AB

Recipharm is a leading contract development and manufacturing partner to the pharmaceutical and biopharmaceutical industries. A top 5 CDMO, we deliver quality services and products, at the right time for our customers and the global markets they serve. 
With significant operations in technically advanced pharmaceutical forms including sterile injectables and inhaled products we are able to support customers from early phase development through scale-up and into commercial manufacture. Our global footprint, comprising over 30 facilities worldwide, means our customers rely on us for support when it comes to accessing new markets.